<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03388645</url>
  </required_header>
  <id_info>
    <org_study_id>180039</org_study_id>
    <secondary_id>18-I-0039</secondary_id>
    <nct_id>NCT03388645</nct_id>
  </id_info>
  <brief_title>Challenge Infection of Healthy Adult Volunteers With RSV A2</brief_title>
  <official_title>Challenge Infection of Healthy Adult Volunteers With RSV A2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      One of the main causes of respiratory infections in children and adults is RSV. This stands&#xD;
      for respiratory syncytial virus. Healthy adults usually get a cold when they get an infection&#xD;
      with RSV. They generally recover without any problems. But some infections can be&#xD;
      life-threatening. Researchers want to study RSV infection in a safe, controlled setting in&#xD;
      healthy adults to help develop new treatments.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To test the safety of a high dose of RSV A2 by spraying the virus into the nose, and studying&#xD;
      how the body responds.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Healthy adults ages 18-50&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened during 2 screening visits with:&#xD;
&#xD;
        -  Medical interview&#xD;
&#xD;
        -  Physical exam&#xD;
&#xD;
        -  Blood and nasal samples&#xD;
&#xD;
        -  Chest X-ray (chest radiograph)&#xD;
&#xD;
        -  Participants will have a heart test. Sticky patches on the body will detect heart&#xD;
           electrical activity.&#xD;
&#xD;
        -  Pulmonary function test (PFT). They will blow into a machine to measure airflow.&#xD;
&#xD;
        -  Urine tests for pregnancy or drug use.&#xD;
&#xD;
      Participants will be admitted to the hospital before they get RSV A2.&#xD;
&#xD;
      Participants will get a single dose of RSV A2 as two sprays, one into each nostril.&#xD;
&#xD;
      Participants will stay in the hospital under isolation for as long as it takes the body to&#xD;
      clear RSV A2 from nasal fluids. This can take as long as 14 days or more.&#xD;
&#xD;
      Participants cannot take any cold medicine to try to feel better.&#xD;
&#xD;
      Every day, participants will:&#xD;
&#xD;
        -  Answer questions about their symptoms&#xD;
&#xD;
        -  Have nasal washes and/or nasal swabs collected&#xD;
&#xD;
        -  Have a physical exam&#xD;
&#xD;
      Participants will have blood drawn most days.&#xD;
&#xD;
      After discharge, participants will keep a health diary.&#xD;
&#xD;
      Participants will have 2 follow-up visits at 1 month and 2 months after receiving the RSV A2&#xD;
      dose. A history and physical examination, a blood draw, and nasal wash and swab will be&#xD;
      performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Respiratory syncytial virus (RSV) is the leading cause of pediatric lower respiratory tract&#xD;
      infection. RSV also causes lower respiratory tract disease in the elderly and&#xD;
      life-threatening disease in immunocompromised hosts. An RSV monoclonal antibody (palivizumab)&#xD;
      is currently available for passive immunoprophylaxis in high-risk infants. Vaccines and&#xD;
      antiviral agents are under development for the treatment and prevention of RSV, but none are&#xD;
      licensed. The ability to challenge healthy volunteers with RSV could rapidly facilitate&#xD;
      efficacy studies of future antivirals and vaccines. In addition, challenge studies would&#xD;
      provide critical information on viral pathogenesis, including types of cells infected,&#xD;
      mucosal and systemic immune response, and alterations in respiratory microbiota. Clinical&#xD;
      trial material for human challenge studies has been prepared from live recombinant&#xD;
      (complementary DNA-derived) RSV of subgroup A (RSV A2).&#xD;
&#xD;
      This study will be a phase 1 study in healthy adult male and non-pregnant female subjects 18&#xD;
      years to 50 years of age. The main purpose of the trial is to define the safety profile,&#xD;
      determine the frequency of RSV shedding in nasal wash, estimate RSV illness rates, and study&#xD;
      immune responses in subjects given 1 dose of 10^7 PFU of RSV A2 challenge virus using a nasal&#xD;
      atomizer. If RSV A2 is found to be sufficiently infectious in adults, then it may be used as&#xD;
      a challenge virus in future studies evaluating antivirals or the protective efficacy of RSV&#xD;
      vaccines, or in studies of the immunopathogenesis of RSV infection.&#xD;
&#xD;
      Subjects will be admitted to the NIH Clinical Center and receive a single intranasal dose of&#xD;
      10^6.3 PFU or 107 PFU of RSV A2. Subjects will remain at the Clinical Center for&#xD;
      approximately 9-14 days after challenge infection undergoing sequential clinical evaluations.&#xD;
      Research specimens, nasal washes and blood, will be collected for various research assays.&#xD;
      Subjects will be discharged when their daily nasal wash RSV result is negative for two days&#xD;
      in a row, and they do not have any signs or symptoms suggestive of possible RSV-associated&#xD;
      lower respiratory tract disease. Subjects will return for follow-up evaluation 28 and 56 days&#xD;
      after viral challenge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2018</start_date>
  <completion_date type="Actual">December 6, 2019</completion_date>
  <primary_completion_date type="Actual">November 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Detectable RSV Shedding in Nasopharyngeal Wash</measure>
    <time_frame>Daily from study Day 2 through day 10 after challenge with RSV A2</time_frame>
    <description>Participants who had shedding of RSV as assessed by detection of RSV A2 in nasal wash by FilmArray multiplex polymerase chain reaction (PCR), by reverse transcriptase (RT)-quantitative PCR, or by quantitative viral culture.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Related, Expected Adverse Events After Challenge</measure>
    <time_frame>Safety assessed continuously during the inpatient phase and at Day 28 and 56 during the outpatient phase of the study</time_frame>
    <description>Participants who had one or more episodes of related, expected adverse events. Participants were evaluated for grades 1 to 3 adverse events. Only grade 1 adverse events were experienced.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Unrelated Expected Adverse Events After Challenge</measure>
    <time_frame>Safety assessed continuously during the inpatient phase and at Day 28 and 56 during the outpatient phase of the study</time_frame>
    <description>Participants who had one or more episodes of unrelated, expected adverse events. Participants were evaluated for grades 1 to 3 adverse events. Only grade 1 adverse events were experienced.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Related, Unexpected Adverse Events After Challenge</measure>
    <time_frame>Safety assessed continuously during the inpatient phase and at Day 28 and 56 during the outpatient phase of the study</time_frame>
    <description>Participants who had one or more episodes of related, unexpected adverse events. Related, unexpected adverse events are those that are not expected but are related to RSV A2 or of grade 4 severity and related to RSV A2. Only grade 1 adverse events were experienced.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Unrelated, Unexpected Adverse Events After Challenge</measure>
    <time_frame>Safety assessed continuously during the inpatient phase and at Day 28 and 56 during the outpatient phase of the study</time_frame>
    <description>Participants who had one or more episodes of unrelated, unexpected adverse events. Unrelated, unexpected adverse events are those that are not expected and are not related to RSV A2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Mild to Moderate Upper Respiratory Illness</measure>
    <time_frame>Daily from study Day 2 through day 10 after RSV challenge</time_frame>
    <description>Participants who experienced mild to moderate upper respiratory illness in healthy volunteers challenged with RSV A2. All RSV illness qualified as mild illness.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Upper Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Low Dose 10^6.3 PFU of RSV A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose 10^7 PFU of RSV A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10^6.3 PFU of RSV A2</intervention_name>
    <description>Each adult volunteer will receive a single intranasal inoculation of 10^6.3 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.</description>
    <arm_group_label>Low Dose 10^6.3 PFU of RSV A2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10^7 PFU of RSV A2</intervention_name>
    <description>Each adult volunteer will receive a single intranasal inoculation of 10^7 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.</description>
    <arm_group_label>High Dose 10^7 PFU of RSV A2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Age 18-50 years inclusive.&#xD;
&#xD;
               2. General good health, without significant medical illness, physical exam findings,&#xD;
                  or significant laboratory abnormalities as determined by the investigator.&#xD;
&#xD;
               3. Willingness to stay confined to the inpatient unit for required study duration.&#xD;
&#xD;
               4. Willingness to have samples stored for future research.&#xD;
&#xD;
               5. Subjects must be of non-childbearing potential (e.g., surgically sterilized&#xD;
                  (bilateral oophorectomy, bilateral tubal ligation, hysterectomy) or, if of&#xD;
                  child-bearing potential and sexually active with a partner who can get them&#xD;
                  pregnant, must have in place an effective method of contraception for at least 30&#xD;
                  days prior to administration of the challenge virus and until 30 days after&#xD;
                  challenge virus&#xD;
&#xD;
                  administration:&#xD;
&#xD;
                    -  intrauterine device (IUD) or equivalent&#xD;
&#xD;
                    -  hormonal contraceptives (e.g., consistent, continuous use of contraceptive&#xD;
                       pill, patch, ring, implant, or injection)&#xD;
&#xD;
                       ---if participant uses contraceptive pill, patch, or ring, they must also&#xD;
                       use a barrier method at the time of potentially reproductive sexual activity&#xD;
                       (e.g., (male/female condom, cap, or diaphragm) plus spermicide)&#xD;
&#xD;
                    -  be in a monogamous relationship with a partner who has undergone a vasectomy&#xD;
                       at least 180 days prior to first dose of study agent&#xD;
&#xD;
               6. A plaque reduction RSV neutralization titer &lt; 8.0 log(2).&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Subject who was previously challenged with RSV A2.&#xD;
&#xD;
          2. Female subject who is pregnant or lactating OR planning to become pregnant from 30&#xD;
             days prior to inoculation through 30 days after inoculation.&#xD;
&#xD;
          3. Presence of self-reported or medically documented significant medical condition(s)&#xD;
             including but not limited to:&#xD;
&#xD;
             -Respiratory disease (e.g., chronic obstructive pulmonary disease, emphysema,&#xD;
             rhinitis, sinusitis) in adulthood, and additionally:&#xD;
&#xD;
             --A history of asthma within the past 5 years, or a current diagnosis of asthma or&#xD;
             reactive airway disease associated with&#xD;
&#xD;
             exercise, seasonal hay fever or allergic rhinitis&#xD;
&#xD;
             --Presence of any febrile illness or symptoms suggestive of a respiratory infection&#xD;
             within 2 weeks prior to inoculation.&#xD;
&#xD;
               -  Any significant abnormality of the nose or nasopharynx, including recurrent&#xD;
                  epistaxis within 90 days prior to viral inoculation or nasal or sinus surgery&#xD;
                  within 180 days prior to viral inoculation.&#xD;
&#xD;
               -  Chronic cardiovascular disease (e.g., congestive heart failure, cardiomyopathy,&#xD;
                  ischemic heart disease).&#xD;
&#xD;
               -  Chronic neurological or neurodevelopmental conditions (e.g., cerebral palsy,&#xD;
                  epilepsy, stroke, seizures).&#xD;
&#xD;
               -  Ongoing malignancy.&#xD;
&#xD;
               -  Chronic medical condition requiring close medical follow-up or hospitalization&#xD;
                  during the past 5 years (e.g., diabetes mellitus, renal dysfunction,&#xD;
                  hemoglobinopathy, autoimmune disease).&#xD;
&#xD;
               -  An immunodeficiency.&#xD;
&#xD;
          4. Use of systemic corticosteroids exceeding 10 mg/day of prednisone equivalent and nasal&#xD;
             steroid preparations or immunosuppressive drugs within 30 days before inoculation and&#xD;
             within 60 days after. Low dose topical steroid preparations used for a discrete period&#xD;
             of time are permitted.&#xD;
&#xD;
          5. Inhaled bronchodilator or inhaled steroid use within the last 360 days or use after&#xD;
             upper respiratory tract infections.&#xD;
&#xD;
          6. Behavioral or cognitive impairment or psychiatric disease that in the opinion of the&#xD;
             investigator affects the ability of the subject to understand and cooperate with the&#xD;
             study protocol.&#xD;
&#xD;
          7. Complete blood count (CBC), aspartate aminotransferase (AST), alanine aminotransferase&#xD;
             (ALT), creatinine values or other screening labs or tests (e.g. electrocardiogram&#xD;
             (EKG), chest x-ray (CXR)) are outside of the NIH Department of Laboratory Medicine&#xD;
             normal reference range and deemed clinically significant by the PI.&#xD;
&#xD;
          8. Positive FDA-approved HIV test obtained during screening procedures.&#xD;
&#xD;
          9. Positive serology for hepatitis C virus obtained during screening period.&#xD;
&#xD;
         10. Presence of hepatitis B surface antigen obtained during screening period.&#xD;
&#xD;
         11. A smoker of tobacco products or a routine marijuana smoker currently or in the past&#xD;
             year.&#xD;
&#xD;
         12. Current alcohol abuse or addiction.&#xD;
&#xD;
         13. Current illicit drug abuse or addiction.&#xD;
&#xD;
         14. Receipt of a licensed vaccine within 30 days prior to RSV A2 inoculation and planned&#xD;
             vaccination within 60 days after inoculation..&#xD;
&#xD;
         15. Receipt of blood or blood-derived products (including immunoglobulin) within 180 days&#xD;
             prior to viral inoculation. Receipt of packed red blood cells given for an emergent&#xD;
             indication in an otherwise healthy person, and not required as ongoing treatment, is&#xD;
             not exclusionary.&#xD;
&#xD;
         16. Receipt of an investigational agent or vaccine within 90 days prior to scheduled RSV&#xD;
             A2 inoculation and planned receipt within 60 days after inoculation.&#xD;
&#xD;
         17. A body mass index (BMI) less than or equal to 18.5 or greater than or equal to 37.0.&#xD;
&#xD;
         18. A medical, occupational, or family problem that would preclude the participant from&#xD;
             complying with all study requirements.&#xD;
&#xD;
         19. Shares household, works closely with, or has routine contact with a child (children) &lt;&#xD;
             5 years of age or with immunocompromised individual(s), adult(s) with significant&#xD;
             cardiopulmonary disease or asthma, institutionalized persons or persons with&#xD;
             functional disability, or any other individual that, in the judgment of the PI, might&#xD;
             be at increased risk for complications if exposed to RSV.&#xD;
&#xD;
         20. Deprived of freedom by an administrative or court order or in an emergency setting.&#xD;
&#xD;
         21. Any condition that in the opinion of the PI would jeopardize the safety or rights of a&#xD;
             person participating in the trial or would render the person unable to comply with the&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lesia K Dropulic, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2018-I-0039.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, McBride S, Lambkin-Williams R, Jordan R, Xin Y, Ramanathan S, O'Riordan T, Lewis SA, Li X, Toback SL, Lin SL, Chien JW. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014 Aug 21;371(8):711-22. doi: 10.1056/NEJMoa1401184.</citation>
    <PMID>25140957</PMID>
  </reference>
  <reference>
    <citation>Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis. 2001 Sep 15;33(6):792-6. Epub 2001 Aug 21.</citation>
    <PMID>11512084</PMID>
  </reference>
  <reference>
    <citation>Lee FE, Walsh EE, Falsey AR, Betts RF, Treanor JJ. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res. 2004 Sep;63(3):191-6.</citation>
    <PMID>15451187</PMID>
  </reference>
  <verification_date>December 6, 2019</verification_date>
  <study_first_submitted>December 30, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <results_first_submitted>November 12, 2020</results_first_submitted>
  <results_first_submitted_qc>November 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 3, 2020</results_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RSV Shedding</keyword>
  <keyword>Immune Responses</keyword>
  <keyword>Neutralizing Antibody Titer</keyword>
  <keyword>Upper Respiratory Tract Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 8, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03388645/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>19 subjects were recruited; 7 were not dosed because they were either ineligible or did not start the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose 10^6.3 PFU of RSV A2</title>
          <description>Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
        </group>
        <group group_id="P2">
          <title>High Dose 10^7 PFU of RSV A2</title>
          <description>Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Low Dose RSV A2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>High Dose RSV A2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose 10^6.3 PFU of RSV A2</title>
          <description>Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
        </group>
        <group group_id="B2">
          <title>High Dose 10^7 PFU of RSV A2</title>
          <description>Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Detectable RSV Shedding in Nasopharyngeal Wash</title>
        <description>Participants who had shedding of RSV as assessed by detection of RSV A2 in nasal wash by FilmArray multiplex polymerase chain reaction (PCR), by reverse transcriptase (RT)-quantitative PCR, or by quantitative viral culture.</description>
        <time_frame>Daily from study Day 2 through day 10 after challenge with RSV A2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose 10^6.3 PFU of RSV A2</title>
            <description>Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
          </group>
          <group group_id="O2">
            <title>High Dose 10^7 PFU of RSV A2</title>
            <description>Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Detectable RSV Shedding in Nasopharyngeal Wash</title>
          <description>Participants who had shedding of RSV as assessed by detection of RSV A2 in nasal wash by FilmArray multiplex polymerase chain reaction (PCR), by reverse transcriptase (RT)-quantitative PCR, or by quantitative viral culture.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Related, Expected Adverse Events After Challenge</title>
        <description>Participants who had one or more episodes of related, expected adverse events. Participants were evaluated for grades 1 to 3 adverse events. Only grade 1 adverse events were experienced.</description>
        <time_frame>Safety assessed continuously during the inpatient phase and at Day 28 and 56 during the outpatient phase of the study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose 10^6.3 PFU of RSV A2</title>
            <description>Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
          </group>
          <group group_id="O2">
            <title>High Dose 10^7 PFU of RSV A2</title>
            <description>Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Related, Expected Adverse Events After Challenge</title>
          <description>Participants who had one or more episodes of related, expected adverse events. Participants were evaluated for grades 1 to 3 adverse events. Only grade 1 adverse events were experienced.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasal congestion or rhinorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinus congestion or pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38°C to 39.4°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Unrelated Expected Adverse Events After Challenge</title>
        <description>Participants who had one or more episodes of unrelated, expected adverse events. Participants were evaluated for grades 1 to 3 adverse events. Only grade 1 adverse events were experienced.</description>
        <time_frame>Safety assessed continuously during the inpatient phase and at Day 28 and 56 during the outpatient phase of the study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose 10^6.3 PFU of RSV A2</title>
            <description>Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
          </group>
          <group group_id="O2">
            <title>High Dose 10^7 PFU of RSV A2</title>
            <description>Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Unrelated Expected Adverse Events After Challenge</title>
          <description>Participants who had one or more episodes of unrelated, expected adverse events. Participants were evaluated for grades 1 to 3 adverse events. Only grade 1 adverse events were experienced.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasal congestion or rhinorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinus congestion or pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Related, Unexpected Adverse Events After Challenge</title>
        <description>Participants who had one or more episodes of related, unexpected adverse events. Related, unexpected adverse events are those that are not expected but are related to RSV A2 or of grade 4 severity and related to RSV A2. Only grade 1 adverse events were experienced.</description>
        <time_frame>Safety assessed continuously during the inpatient phase and at Day 28 and 56 during the outpatient phase of the study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose 10^6.3 PFU of RSV A2</title>
            <description>Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
          </group>
          <group group_id="O2">
            <title>High Dose 10^7 PFU of RSV A2</title>
            <description>Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Related, Unexpected Adverse Events After Challenge</title>
          <description>Participants who had one or more episodes of related, unexpected adverse events. Related, unexpected adverse events are those that are not expected but are related to RSV A2 or of grade 4 severity and related to RSV A2. Only grade 1 adverse events were experienced.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postnasal drip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smell alteration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taste alteration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Throat irritation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Watering eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Unrelated, Unexpected Adverse Events After Challenge</title>
        <description>Participants who had one or more episodes of unrelated, unexpected adverse events. Unrelated, unexpected adverse events are those that are not expected and are not related to RSV A2.</description>
        <time_frame>Safety assessed continuously during the inpatient phase and at Day 28 and 56 during the outpatient phase of the study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose 10^6.3 PFU of RSV A2</title>
            <description>Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
          </group>
          <group group_id="O2">
            <title>High Dose 10^7 PFU of RSV A2</title>
            <description>Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Unrelated, Unexpected Adverse Events After Challenge</title>
          <description>Participants who had one or more episodes of unrelated, unexpected adverse events. Unrelated, unexpected adverse events are those that are not expected and are not related to RSV A2.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive disturbance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laceration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Light headedness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low back pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle soreness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Night sweats</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Syncope</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiredness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Mild to Moderate Upper Respiratory Illness</title>
        <description>Participants who experienced mild to moderate upper respiratory illness in healthy volunteers challenged with RSV A2. All RSV illness qualified as mild illness.</description>
        <time_frame>Daily from study Day 2 through day 10 after RSV challenge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose 10^6.3 PFU of RSV A2</title>
            <description>Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
          </group>
          <group group_id="O2">
            <title>High Dose 10^7 PFU of RSV A2</title>
            <description>Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Mild to Moderate Upper Respiratory Illness</title>
          <description>Participants who experienced mild to moderate upper respiratory illness in healthy volunteers challenged with RSV A2. All RSV illness qualified as mild illness.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>56 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Dose 10^6.3 PFU of RSV A2</title>
          <description>Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
        </group>
        <group group_id="E2">
          <title>High Dose 10^7 PFU of RSV A2</title>
          <description>Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Respiratory rate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Taste disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lesia Dropulic</name_or_title>
      <organization>National Institute of Allergy and Infectious Diseases</organization>
      <phone>+1 301 496 7675</phone>
      <email>dropulicl@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

